{"id":"NCT01218438","sponsor":"Baxalta now part of Shire","briefTitle":"Phase 2/3 Study of IGSC, 20% in PIDD","officialTitle":"A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2013-01-28","primaryCompletion":"2015-03-13","completion":"2015-03-13","firstPosted":"2010-10-11","resultsPosted":"2017-02-15","lastUpdate":"2021-07-20"},"enrollment":86,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immunodeficiency Diseases (PID)"],"interventions":[{"type":"BIOLOGICAL","name":"Immune Globulin Intravenous (Human), 10% Solution","otherNames":["IGIV","10%"]},{"type":"DRUG","name":"Immune Globulin Subcutaneous (Human), 20% Solution","otherNames":["IGSC","20%"]}],"arms":[{"label":"Study Epochs 1-4","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to develop a 20% subcutaneous (SC) immunoglobulin preparation for the treatment of patients with primary immunodeficiency diseases (PIDD).","primaryOutcome":{"measure":"Rate of Acute Serious Bacterial Infections Per Year (ASBI)","timeFrame":"1 year","effectByArm":[{"arm":"Study Participants","deltaMin":0.012,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":18},"locations":{"siteCount":18,"countries":["United States","Canada"]},"refs":{"pmids":["22566844","10600329","34036490","31268374","31228628","30626238","27582171"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":77},"commonTop":["Headache","Sinusitis","Upper respiratory tract infection","Acute sinusitis","Nausea"]}}